He said the Patanjali Group would focus on six sectors natural medicine, natural food, natural cosmetics, dairy products, cattle feed and natural manure in a big way.

Domestic equity markets are likely to open flat tracking SGX Nifty on the Singapore Stock Exchange.

Money Today brings you investing lessons from the world's greatest value investors such as Warren Buffett, Benjamin Graham and David Dreman and 10 stocks that pass the tough quality tests prescribed by investing legend John Neff.

A Business Today study of more than 6,000 stocks came up with a startling finding: only six of these companies have paid dividends of more than 30 per cent of their net profit in the past decade, as well as outperformed the benchmark index for eight of those 10 years.

Thanks to a differentiated business model, Emami has been able to enhance shareholder wealth over the decades, says Naresh Bhansali is CEO (Finance, Strategy and Business Development) at Emami.

Kamal Kishore Baheti, Director and CFO, McLeod Russel; Naresh Bhansali, CEO (Finance, Strategy and Business Development), Emami; and A.K. Mukherjee, Director - Finance and CFO, Exide Industries.

For the year ended March 31, 2012, the company posted a net profit of Rs 258.81 crore, compared to Rs 228.71 crore in 2010-11.

The country's top number crunchers talk about their winning approach.

Eleven more companies that are strongly placed to turn Goliaths in a few years.

Last year, British consumer goods firm Reckitt Benckiser had acquired Paras Pharmaceuticals for Rs 3,260 crore ($726 million). Emami was in the race to buy the Ahmedabad-based firm.

FMCG companies are tapping opportunities in the growing consumer healthcare market, one of the many categories that blur the distinction between fast-moving consumer goods and pharmaceuticals.

The US space research agency NASA has warned that solar flares in 2013 could wreck global satellite communication and knock out electricity grids, causing blackouts in major parts of the world.

29.4 per cent is the return from Zandu Pharmaceutical stock since Jan 2008. The Sensex during the same period lost 52%.

Pharma stocks have gained momentum because of robust first-quarter earnings.

The Smallcap index has shed half its value in the past six months, and the blue-chip sensitive index contained losses to a third of its value.

GlaxoSmithKline rules the malted food drinks segment and has a comfortable presence in pain relievers and antacids. So, why is it acting like an insecure underdog?

The promoters of Zandu Pharma and Fem Care Pharma recently sold their stakes at attractive valuations. All the deals were struck above the prevailing stock prices of the two companies, an enviable feat considering the depressed economic and market conditions.

Will Emami’s acquisition of Zandu Pharma change the landscape of the consumer products sector?

The battle for control of Zandu is good for small shareholders.

As stock prices crumble, M&A activity begins to pick up. Investment bankers say several cash-rich corporates are on the hunt for companies in high-growth sectors, but whose stocks have taken a battering.